Effects of acute elevation of circulating fatty acids on hepatic lipid accumulation and metabolism in overweight and obese men with non-alcoholic fatty liver disease - Elevated circulating FFA and intrahepatic lipid content.

niversiteit Maastricht0 个研究点目标入组 22 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•- Age 40-65 years
•- Overweight/obese, BMI 25-35 kg/m2
•- Stable dietary habits
•- Must be on sulphonylurea or metformin therapy for at least 6 months with constant dose for at least 2 months, or on a dietary treatment for at least 6 months
•- Well-controlled diabetes: fasting plasma glucose concentration >= 7.0 mmol/l and < 10.0 mmol/l at the time of screening.

•Persons that have any of the following will be excluded from the study:
•- Female sex
•- Haemoglobin <7.8 mmol/l
•- Engagement in programmed exercise > 2 hours total per week
•- Liver disease, other than NAFLD
•- Hypertension: blood pressure > 160 mmHg systolic or 100 mmHg diastolic
•- Cardiac problems, such as angina pectoris, cardiac infarction and arrhythmias
•- First degree relatives with history of liver disease and diabetes mellitus
•- Alcohol consumption of more than 20 g per day (± 2 units)
•- Unstable body weight (weight gain or loss > 3 kg in the past three months)
•- Participation in another biomedical study within 1 month prior to the screening visit
•- Insulin use
•- Contraindications for MRI scan:
•Central nervous system aneurysm clips
•Implanted neural stimulator
•Implanted cardiac pacemaker of defibrillator
•Cochlear implant
•Iron- containing corpora aliena in the eye or brain
•Hearing aids and artificial (heart) valves which is contraindicated for MRS
•- Subjects, who do not want to be informed about unexpected medical findings, or do not wish that their treating physician is informed, cannot participate in the study
•- Liver fat content lower than 5.56%

发起方